Tomkiel Melissa M.'s Form 4 filing
Strata Critical Medical, Inc. (SRTA) · filed Apr 11, 2023
- Accession no.
- 0001779128-23-000041
- Filed
- Apr 11, 2023
- Trade date
- Apr 5-10, 2023
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $115.7K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tomkiel Melissa M.CIK 0001859484 | Officer (President and General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2023 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −12,151 | $2.98F2 | −$36,209.98 | 1,427,102 | Direct | |
| Apr 6, 2023 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −9,361 | $2.92F3 | −$27,334.12 | 1,417,741 | Direct | |
| Apr 10, 2023 | Class A common stock, $0.0001 par value per share | SSaleDisposed | −18,439 | $2.83F4 | −$52,182.37 | 1,399,302 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.825 to $3.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.87 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.805 to $2.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
The sales reported on this Form 4 were effected pursuant to a contract, instruction or written plan adopted prior to February 27, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) as in effect on the date of adoption.